{"disease":{"id":"advanced-metastatic-castration-resistant-prostate-cancer","name":"advanced metastatic castration resistant prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT04606446","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07570966","title":"Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":217,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07288359","title":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06217822","title":"First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05888532","title":"64Cu-GRIP B in Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT03682289","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT06609005","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Shenzhen Ionova Life Sciences Co., Ltd.","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT03493945","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07189403","title":"A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03861403","title":"A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Leap Therapeutics, Inc.","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}